Identification of Down's syndrome critical locus gene SIM2-s as a drug therapy target for solid tumors -- Data Supplement - Supporting Figures -- Proceedings of the National Academy of Sciences

Supporting information for De Young et al. (2003) Proc. Natl. Acad. Sci. USA, 10.1073/pnas.0831000100

JPEG Image

Fig. 5.
Lack of toxicity of the SIM2-s antisense in primary cells. Early passage human renal cortical epithelial cells (HRCE) or prostate epithelial cells (PrEC) were treated with 300 nM of either the control (C) or the antisense (AS) to SIM2-s gene for 72 h and were photomicrographed (×130).